Drugplain

BACTERIOSTATIC SODIUM CHLORIDE 9 mg/mL

SODIUM CHLORIDE · INJECTION, SOLUTION · Hospira, Inc.

No Recall HistoryCurrently in Shortage
Plain English

BACTERIOSTATIC SODIUM CHLORIDE is a injection, solution containing sodium chloride at 9 mg/mL, taken intramuscular. Manufactured by Hospira, Inc..

Key Facts

Brand Name
BACTERIOSTATIC SODIUM CHLORIDE
Generic Name
SODIUM CHLORIDE
NDC Code (Product)
0409-1966
Manufacturer
Hospira, Inc.
Strength
9 mg/mL
Dosage Form
INJECTION, SOLUTION
Route
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Marketing Status
Application #
NDA018800
Marketing Start
04/30/2005

Recall History

No Recall History

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE This parenteral preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.

Dosage & Administration

DOSAGE AND ADMINISTRATION The volume of the preparation to be used for diluting or dissolving any drug for injection, is dependent on the vehicle concentration, dose and route of administration as recommended by the manufacturer. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.

Warnings

WARNINGS Benzyl alcohol, a preservative in Bacteriostatic Sodium Chloride Injection, USP has been associated with toxicity in neonates. Data are unavailable on the toxicity of other preservatives in this age group. Preservative-free Sodium Chloride Injection should be used for flushing intravascular catheters. Where a sodium chloride solution is required for preparing or diluting medications for use in neonates, only preservative-free Sodium Chloride Injection should be used.

Contraindications

CONTRAINDICATIONS Due to the potential toxicity of benzyl alcohol in neonates, solutions containing benzyl alcohol must not be used in this patient population. Parenteral preparations with benzyl alcohol should not be used for fluid or sodium chloride replacement. Parenteral preparations containing benzyl alcohol should not be used in epidural or spinal anesthetic procedures.

Adverse Reactions

ADVERSE REACTIONS Reactions which may occur because of this solution, added drugs or the technique of reconstitution or administration include febrile response, local tenderness, abscess, tissue necrosis or infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate countermeasures, and if possible, retrieve and save the remainder of the unused vehicle for examination. Although adverse reactions to intravenous, intramuscular or subcutaneous injection of 0.9% benzyl alcohol are not known to occur in man, experimental studies of small volume parenteral preparations containing 0.9% benzyl alcohol in several species of animals have indicated that an estimated intravenous dose up to 30 mL may be safely given to an adult without toxic effects. Administration of an estimated 9 mL to a 6 kg neonate or infant is potentially capable of producing blood pressure changes.

Frequently Asked Questions

What is BACTERIOSTATIC SODIUM CHLORIDE used for?

BACTERIOSTATIC SODIUM CHLORIDE contains SODIUM CHLORIDE. It is a injection, solution taken intramuscular. Consult your doctor for specific uses.

Is BACTERIOSTATIC SODIUM CHLORIDE a controlled substance?

BACTERIOSTATIC SODIUM CHLORIDE is not classified as a controlled substance by the DEA.

What is the generic name for BACTERIOSTATIC SODIUM CHLORIDE?

The generic name for BACTERIOSTATIC SODIUM CHLORIDE is SODIUM CHLORIDE. There are 12 other brand versions of SODIUM CHLORIDE.

What is the NDC code for BACTERIOSTATIC SODIUM CHLORIDE 9 mg/mL?

The NDC (National Drug Code) for BACTERIOSTATIC SODIUM CHLORIDE 9 mg/mL is 0409-1966, listed by Hospira, Inc..